Thursday, 21 July 2016

Global Primary Care Doctor Market Current Industry Trends & Opportunities

Primary care doctors are the licensed healthcare professionals who diagnose and treat individuals, and help them in restoring their health condition, and thus bring them back to the active life through reducing the physiological complications and restoring the body functions. They are the primary point of advice for the patients due to a number of factors like easy communication, familiarity and the need of cost management. They may refer the patients to a specialized care for the further treatment process. They prescribe a particular diagnosis for the patient and interpret results from it, and thus they formulate a plan, a medication, therapy, referral to specialist and follow-up the results of treatment.  Primary care doctors are present in hospitals, private practices, outpatient clinics, home health agencies, and nursing homes. The activities by the doctors in the industry includes examining the patient’s history, designing the technique or management plan, incorporating the results and providing therapy and education. 


Based on various types of treatment, the Primary care market can be segmented as follows:
  • Family Medicine Doctors: They are board certified to check-up people of all ages.
  • Internal Medicine Doctors: They check-up people above 14 years of age. They check internal organs of the body and prescribes medicine for it. Some of them can also provide care for gynecology and dermatology.
  • Gynecologist or Obstetrician: These physicians provide special care to the women during and after the reproductive phase. Almost all Gynecologists have specialty in Obstetrics.
  • Geriatricians: These physicians have special education to treat adults over 60. They provide medication management and mental assessment related falls and other aging issues.
  • Pediatricians: There are certified to diagnose and treat children from newborn through age 21, through a wide range of diseases.
Some of the major driving factors for the market growth include rising aging population and increasing prevalence of chronic health conditions. Due to the federal healthcare reform, there is high rate of private insurance which made the private healthcare services much affordable for the U.S. population.

Geographically, the Primary care doctors market can be segmented into six major regions: North America, Europe, Asia Pacific, Latin America, Middle East and Rest of the World (RoW). North America holds the leading position in the Primary care doctors market followed by Europe. Stronger primary care would be an important policy goal by the Senate Finance Committee and House Ways and Means Committee in U.S. because primary care practices that have been redesigned to ensure the provision of patient-centered, coordinated care is a key of high-performance health system. Key factors responsible for their dominance in this market are high aging population, increasing active lifestyle of people, high healthcare expenditure by the government, reimbursement policy and the presence of huge number of physicians. In 2015, there are around 176,893 primary care doctors in Internal Medicine licensed in the U.S. Asia Pacific is the most promising market for the growth of Primary care doctors market due to various emerging economies. Although there are many challenges for primary care physicians like misdistribution and decreasing quality of care measures, key factors contributing towards the growth of the market in these regions include easy market penetration, favorable reimbursement scenario, cheap medication and development of various healthcare infrastructures such as hospitals, clinics, etc.

Monday, 27 June 2016

Rise in Geriatric Population will Fuel Expansion of Global Nurse Call Systems Market at 13.90% CAGR

A new Transparency Market Research report states that the global nurse call systems market stood at US$0.6 bn in 2013 and is anticipated to reach US$1.6 bn by 2020. It is expected to expand at a CAGR of 13.90% from 2014 to 2020. The title of the report is “Nurse Call Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.”

Get a Free Sample Report: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2173

According to the report, factors such as the rising aging population and the growing need for responsive and efficient healthcare communication are amongst the major factors propelling the growth of the market for nurse call systems. In addition, the globally rising budget allocation in healthcare for elderly people is also a prime factor augmenting the growth of the market. In addition, the rise of the Internet of Things (IoT) within healthcare infrastructure has emerged as a key opportunity in the market. On the other hand, government regulations on distribution and manufacturing of nurse call systems are amongst the major factors impeding the growth of the market.

In terms of equipment type, the market is segmented into nurse call intercoms, nurse call buttons, nurse call integrated communication systems, and nurse call mobile systems. Amongst these, the segment of nurse call integrated communication systems led the market in 2013. On the other hand, the segment of nurse call mobile systems is predicted to expand at the highest growth rate in the forecast horizon owing to the rising demand for mobile solutions.

On the basis of communication technology, the report segments the market into wireless communication equipment and wired communication equipment. Amongst these, wired nurse call communication equipment dominated the market for nurse call systems in 2013. On the other hand, the demand for wireless nurse call communication equipment is poised to rise in the forecast horizon owing to the rising demand for flexibility and mobility in communication.

On the basis of end use, the nurse call systems market is segmented into OPD clinics, hospitals, ambulatory services, and assisted living centers. Amongst these, in 2013, the segment of hospitals constituted a share of approximately 74% in the market on the basis of revenue. On the other hand, factors such as the requirement for effective communication systems and patient safety will raise the demand for nurse call systems within the segment of assisted living centers in the forecast horizon.

Geographically, the market is segmented into Europe, North America, Asia Pacific, and Rest of the World (RoW). Amongst these, in 2013, North America held the largest share in the market on the basis of revenue. This is due to the rising adoption of nurse call systems within this region in numerous healthcare settings. Europe trailed North America and stood as the second largest market for nurse call systems on the basis of revenue in the same year. However, the market for nurse call systems is poised to experience sluggish growth in this region in the coming years owing to slow economic growth.

The chief players dominant in the market are Rauland-Borg Corporation, Stanley Healthcare, Hill-Rom Holdings, Inc., Tyco SimplexGrinnell, Ascom Holding AG, Cornell Communications, Inc., Azure Healthcare Limited, Jeron Electronic Systems, Inc., and Vigil Health Solutions, Inc., among others.

Full Research Report on Global Nurse Call Systems Market: 
http://www.transparencymarketresearch.com/nurse-call-system-equipment-market.html

Wednesday, 22 June 2016

Disruptive Behavior Disorders Market Growth Drivers 2023


Transparency Market Research provides a thorough analysis of the global disruptive behavior disorders market through its new research report. The report, titled “Disruptive Behavior Disorders Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,” assesses the factors driving the overall market and the ones restraining it. The researchers have used a SWOT analysis to highlight the strengths, weaknesses, opportunities, and threats impacting the segments of the overall market. Additionally, the document also includes a trajectory of the global disruptive behavior disorders market by analyzing several journals, new articles, and research papers.


Disruptive behavior disorders are characterized by adamant and unfriendly behavior, which becomes an impediment to the normal functioning of the individual. Persons suffering from these disorders exhibit temper tantrums, physical aggression, excessive disagreement, depression, poor attention span, and other symptoms that borderline resistance towards regular activities and people. Oppositional defiant disorder (ODD) and conduct disorder (CD) are the two main branches of disruptive behavior disorders, which show prominent abnormal social skill sets and an inability to function in regular circumstances. Undiagnosed disruptive behavior disorders can intensify symptoms, posing as a serious harm to the patient’s life and to those around them.

The global disruptive behavior disorders market has been assessed on the basis of therapeutics and geography. The therapeutics segment is further divided into target molecules, administration, and mechanism of action and safety of the drugs. SPN-812, SUVN-502, AZ-5213, and ORADUR-ADHD are some of the drugs under investigation in the overall market. Geographically, this market is segmented into Asia Pacific, North America, Europe, and Rest of the World.

The global disruptive behavior disorders market is being driven by the rise in the number of comorbid disorders, which can be exceptionally dangerous, if untreated. Furthermore, the increasing investments made by pharmaceutical companies to develop effective drugs and therapeutics are also expected to propel this market in the coming years. However, the poor rate of diagnosis and the improper approaches towards treatments are likely to restrain the growth of this market in the coming years.

Some of the key players in the global disruptive disorders market are Eli Lilly and Co., Pfizer, Inc., Johnson & Johnson, DURECT Corporation, Bionomics Ltd., and Chelsea Therapeutics, Inc. The research report profiles these players to provide the competitive landscape of the global market and explain the nature of expansion styles used by these players to gain a competitive edge. Furthermore, the research report also evaluates the financial overview, research and development strategies, business and marketing strategies, and strategic mergers and acquisitions of these companies for the coming few years.

Full Research Report on Global Disruptive Behavior Disorders Market: 
http://www.transparencymarketresearch.com/disruptive-behavior-disorders-market.html

Tuesday, 14 June 2016

3D Bioprinting Market Demand in Medical and Healthcare Sector


A new study by Transparency Market Research (TMR), titled “3D Bioprinting Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024,” states that the increasing application of 3D bioprinting technology in the medical and healthcare sectors across the world is the key driver of the worldwide market.


Apart from this, the increasing lifespan of individuals, the rising prevalence of chronic illnesses, the growing demand for tissue and organ transplants, the integration of information technology into the medical and healthcare sector, dearth of organ donors, advancements in 3D printing technology, and the augmenting base of the geriatric population are also driving the worldwide market for 3D bioprinting significantly, states the research study.

The report has also discussed the prospects of the global 3D bioprinting market at length. As per the study, the increasing requirement of regenerated tissues, organs, implants, and prosthetics are likely to present a lucrative opportunity for market players during the forecast period. In addition to this, the emergence of 3D bioprinted pills is projected to open new avenues for them in the coming years. The augmenting need for customized medicines and the rapid rise in the production of biodrugs are also anticipated to drive the market in the near future.

According to the report, the global market for 3D bioprinting is spread across Asia Pacific, North America, Europe, and the Rest of the World. North America leads the worldwide market in terms of revenue. The presence of an advanced medical and healthcare infrastructure, a large pool of chronically ill patients, and high spending power of people in this region is boosting the North America 3D bioprinting market significantly.

Analysts predict this regional market to retain its dominance during the forecast period, owing to continual research activities in the area of 3D printing. However, Asia Pacific is likely to surface as a strong contender for leadership in the global market for 3D bioprinting in the coming years. 

The rapid rise in the adoption advanced technologies, advancements in healthcare IT, favorable government initiatives, increasing foreign investments, and the growing awareness regarding 3D bioprinting technology are anticipated to propel the Asia Pacific 3D bioprinting market over the forecast period, states the report.

The research report has also analyzed the profiles of major companies operating in the global 3D bioprinting market and determined the current market hierarchy. Oceanz, Organovo Holding Inc., Luxexcel Group BV, TeVido BioDevices, Stratasys Ltd., Voxeljet, Solidscape, Aspect Biosystems, Materialise NV, Bio3D Technologies Pte Ltd., Cyfuse Biomedical, 3Dynamics Systems, BioBots, and Envision TEC are some of the key market players mentioned in this study.

Monday, 30 May 2016

Usage in Companion Diagnostic Services Stimulates Global Transcriptomics Market to Reach US$4.6 Billion by 2019

Transparency Market Research, a global market intelligence consultancy, has published a market study on the global transcriptomics technologies market for the 2013-2019 period. According to this report, the global transcriptomics technologies market will rise at a CAGR of 15.90% from 2013 to 2019 to reach a valuation of US$4.6 bn by the end of the forecast period. The market’s valuation in 2012 was US$1.65 bn. The report is titled “Transcriptomics Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019”.

Get Free Sample Research Report: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1659
 
The report says that the global transcriptomics technologies market will witness substantial growth in the coming years due to several reasons. Transcriptomics research involves studying the structure and function of RNA present in a cell.Presently, transcriptome analysis of several organisms is assisted using next-generation sequencing platforms in the preliminary phase followed by polymerase chain reactions, gene regulation technologies, and microarrays in the latter part. The coalition of these technologies is used for drug discovery, clinical diagnosis of diseases, medical research, and others. With the ever-increasing demand for targeted therapeutics and continual improvement of healthcare infrastructure, the commercial usage of transcriptomics technologies holds promise. Transcriptomics research allows the development of newer therapeutics and diagnostics and further advancement of the existing line of treatment for medical conditions.

The report says that in the transcriptomics technologies market, the key application segments undergo consistent development in order to offer added value to users. For instance, the utilization of transcriptomics technologies has benefitted the pharmaceutical and biotechnology fields; other fields are also deriving the advantages of this technology for mutual benefits of both the technology and the application field. Laboratories attempting to use biomarkers and newer gene sequencing methods is an example of this.

The need for the development of adequate equipment in healthcare organizations and laboratories, the growing awareness about transcriptomics technologies globally, and increased participation of government bodies in transcriptomics research are some other factors driving this global market.

However, growth of the transcriptomics technologies market is hampered due to certain factors cited in this report. These include the unavailability of advanced equipment needed for biological computation, unavailability of services essential to analyzing complex information, and an overall deficit of technicians that have expertise in the subject.

The report divides the global transcriptomics technologies market into the regional segments of North America, Asia Pacific, Europe, and Rest of the World. Among the regional segments, Asia Pacific will exhibit a substantial uptake of these technologies and the fastest growth rate in the transcriptomics technologies market during the forecast period. Ongoing infrastructural development for improved healthcare and increased acceptance of novel biotechnology research are the reasons for this.

In 2012, North America led the global transcriptomics technologies market, contributing more than 35% of the revenue in the global market. The presence of advanced healthcare infrastructure, which includes well-equipped research facilities, increased awareness of biotechnology research, and the high number of initiatives taken by governments to promote research activities are the reasons for the dominant position of North America in this market.

The report mentions the top players that operate in the global transcriptomics market. These are Life Technologies Corporation, F-Hoffmann La Roche Ltd., Thermo Fisher Scientific, Illumina Inc., Agilent Technologies, and Affymetrix Inc.

Full Research Report on Global Transcriptomics Technologies Market: 
http://www.transparencymarketresearch.com/transcriptomics-technologies-market.html

Wednesday, 25 May 2016

Global Upper Respiratory Tract Disorder Diagnostics and Therapeutics Market

Respiratory disease is a medical condition that includes pathological conditions that affect tissues and organs which assist in making gas exchange possible in the organisms. Respiratory disease ranges from self-limiting and mild, such as the common cold, to life-threatening conditions such as lung cancer, pulmonary embolism and bacterial pneumonia. Various respiratory disease conditions include disorder of upper respiratory tract, bronchi, bronchioles, trachea, pleura and pleural cavity, alveoli, and the nerves and muscles of breathing.


Upper respiratory tract disorder or infection (URI or URTI) is a medical condition caused by acute infection that involves upper respiratory tract such as sinuses, nose, larynx or pharynx. Pharyngitis, tonsillitis, sinusitis, laryngitis, common cold, and otitis media are some of the most common upper respiratory tract disorders. Upper respiratory tract disorders are caused by direct invasion of the mucus membrane (inner respiratory tract lining) by bacteria or virus. Rhinorrhea, sneezing, nasal congestion, nasal discharge, sore throat, cough, fever, odynophagia and malaise are some of the most common symptoms observed in the patient diagnosed with upper respiratory tract disorder. Some other symptoms of the disease are headache, foul breath, hyposmia, sinus pain, shortness of breath, conjunctivitis, vomiting diarrhea, nausea, and body ache.

Upper respiratory tract disorder can be diagnosed by physical examination, laboratory tests and review of symptoms. In physical examination, physicians look for redness and swollen inside the wall of nasal cavity, white secretions on the tonsils, redness of the eyes, redness of the throat, and enlarged lymph nodes around neck and head. Laboratory testing is usually not performed for examining upper respiratory tract disorders as most of the upper respiratory tract infections are caused by viruses and no specific treatment for different types of viral upper respiratory tract disorder is available in current scenario. Some of the laboratory tests that are performed for diagnosing upper respiratory tract disorder include imaging tests (X-ray and CT scan), blood tests and sputum tests.

Upper respiratory tract disorders can be treated with antibiotics and decongestants. Acetaminophen, ibuprofen, diphenhydramine, dextromethorphan, codeine, guaifenesin, dexamethasone and prednisone are some of the antibiotics that are prescribed to the patients suffering from upper respiratory tract disorders. Oxymetazoline, phenylephrine and pseudoephedrine are some of the most commonly prescribed decongestants for the treatment of upper respiratory tract disorders. Antibiotics are rarely used as a treatment option for upper respiratory tract disorders as they are associated with many side effects and also can initiate secondary infections and bacterial resistance.

The market for upper respiratory tract disorder diagnostics and therapeutics is expected to grow at a significant CAGR during the forecast period from 2014 to 2020 owing to increasing incidences of respiratory disorders across the globe. Similarly, constant changing climate condition due to global warming and pollution has further accentuated the risk for developing upper respiratory tract disorders. This in turn is expected to drive the growth of upper respiratory tract disorder diagnostics and therapeutics market. Currently, North America accounts for the largest share of the global upper respiratory tract disorder diagnostics and therapeutics market. This is due to the fact that the U.S. has witnessed for large patient pool suffering from upper respiratory tract disorders. 
Some of the major players operating in upper respiratory tract disorder diagnostics and therapeutics market include Alcon, Inc., Merck & Co., Inc., Collegium Pharmaceutical, Inc., GlaxoSmithKline plc and Verona Pharma Plc among other significant players across the globe.

Full Research Report on Global Upper Respiratory Tract Disorder Diagnostics and Therapeutics Market: 
http://www.transparencymarketresearch.com/upper-respiratory-tract-disorder-diagnostics-therapeutics.html

Tuesday, 24 May 2016

M2M Connected Healthcare Market: Global Industry Trends and Forecast 2014 - 2020


Over the past few years, the healthcare industry has been witnessing increasing adoption of machine to machine (M2M) technology in order to reduce skyrocketing healthcare costs,   increase adherence to medical regimens and improve better patient care. M2M connected healthcare is a healthcare delivery model that operates in an IT ecosystem, and allow easy access and sharing of healthcare related data such as patient medical history data, patient personal information, prescription information, diagnostic results, clinical data and others. Home monitoring, clinical monitoring, assisted living and telemedicine are among the major functions carried out by M2M connected healthcare systems. M2M connected healthcare saves time by connecting patients, healthcare providers and treatment systems over the internet. The M2M connected healthcare systems can use wired or wireless connectivity to share healthcare data between web-connected devices without the need of human involvement.


The global market for M2M connected healthcare has been segmented into home monitoring, clinical monitoring, clinical trials, telemedicine, assisted living, worried well and clinical remote monitoring. Significant advantages associated with M2M connected healthcare have been identified as the major factors driving the M2M connected healthcare market growth. These advantages include reduced time, reduced healthcare cost, easy sharing of healthcare data and remote healthcare monitoring. M2M model also enables patients with more control over their treatment regime. Globally rising incidences of various chronic diseases such as diabetes, cancer and hypertension are also expected to play a key role in driving the market growth during the forecast period from 2014 to 2020. Persistent rise in geriatric population directly impacts the growth and development of connected health M2M services as elderly population is highly susceptible to acquire several health disorders as compared to younger adults. According to World Health Organization (WHO) projections, in 2010, global geriatric population was around 524 million and is anticipated to reach around 1.5 billion by the year 2050. Thus, a consistent rise in geriatric population would boost the growth of M2M connected healthcare market as they will increasingly seek M2M connected health services. One of the major factors that are expected to affect the market growth is that stake holders should have access to internet connection.

In terms of geography, the global market for M2M connected healthcare has been segmented into four major regions, namely, North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW). North America represented the largest regional market for M2M connected healthcare in 2013. Well established healthcare infrastructure of the North American countries U.S. and Canada, and presence of a large pool of technically-savvy patient population are among the major factors responsible for North America’s leading position in this market segment. Europe represented the second largest market after North America. Germany, France, United Kingdom, Italy and Spain are the most potential markets in the European region that accounted for more than 60% of the overall Europe M2M connected healthcare market. During the forecast period from 2014 to 2020, APAC is expected to witness significant growth as M2M connected healthcare model will help in serving patients residing in remote area, overcoming distance barriers.

Allscripts, IBM, Apple, AirStrip Technologies, Cisco Networks, Microsoft, AT&T, BL Healthcare, Ingenious Med, NeuroVigil, PharmaSecure, QxMD Software, WellDoc and ObTech Medical are among the major players operating in this market. These players are competing with each other in order to get competitive advantages over others.

Full Research Report on Global M2M Connected Healthcare Market: 
http://www.transparencymarketresearch.com/m2m-connected-healthcare-market.html

Monday, 22 June 2015

Psoriatic Arthritis Pharmacotherapy Market Segment Forecasts up to 2020, Research Reports

Psoriatic Arthritis is a type of chronic inflammatory arthritis that primarily affects toes and fingers followed by nail or skin psoriasis. The clinical features are varied but the major symptoms are peripheral arthritis, enthesitis, psoriasis, dactylitis and axial disease. According to Arthritis Foundation, the prevalence of psoriatic arthritis in patients suffering from psoriasis is approximately between 7% and 48%. Psoriatic arthritis appears most often between the age of 30 years and 50 years. The factors contributing to the pathogenesis of psoriatic arthritis are genetic factors, environmental factors and immunological factors. Genetic factors explain that 40% of the psoriatic arthritis has family history of skin and joint diseases. Environmental factors such as bacterial and viral infections have been implicated as a cause in psoriatic arthritis. Immunological factors consist of cytokines such as TNF-α which is critically involved in inflammatory process, leading to bone and cartilage degradation as well as skin inflammation. There are five different types of psoriatic arthritis that includes different joints and spinal column. There are two types of method by which psoriatic arthritis is diagnosed by imaging and laboratory test. Imaging tests consist of X-Rays and magnetic resonance imaging and laboratories consists of rheumatoid factor and joint fluid test.


The pharmacotherapy of psoriatic arthritis consists of drugs such as DMARDs (disease modifying anti-rheumatic drugs), NSAIDs, Immunosuppressant and TNF-α inhibitors. In chronic conditions surgeries and other procedures are practiced such as steroid injections and joint replacement surgery. The DMARDs consists of drug that reduces the progression of psoriatic arthritis and protect joints and other tissues from irreversible damage, it includes drugs such as methotrexate, sulfasalazine and leflunomide. The NSAIDs help to relive the pain and reduction of inflammation and most of them are OTC drugs including Ibuprofen and naproxen sodium. While immunosuppressant helps to control the immune system including azathioprine and cyclosporine. TNF-α inhibitors assist reducing pain, swollen joints and morning stiffness this class of drug includes etanercept, infliximab, adalimumab, Humira, certolizumab and golimumab.

Some of the major factors driving the psoriatic arthritis market are rising geriatric population, increasing incidences of psoriatic arthritis and major onset for growth in this market is expected from the launch of blockbuster drugs such as Simponi and Vicodin along with many impending biologics that are in late stage of development. The major factors restraining the growth of psoriatic arthritis pharmacotherapy market are the new biologics that are observed to be highly efficient but come with high cost. Lack of patient awareness is one of the major factor affecting the growth of psoriatic arthritis pharmacotherapy market according to CDC (Center of Disease Control and Prevention) nearly 10% - 12% of the patients visit clinics during the chronic stage of psoriatic arthritis as most of them ignore initial symptoms which are very common like skin reddening along with a joint pain or a skin rash.

North America was observed to be the leading geography due to high prevalence of psoriatic arthritis followed by availability of modern healthcare facilities is assisting the growth of this market. Europe is the second largest market for psoriatic arthritis pharmacotherapy as it’s the region expected to observe rapid aging population. Asia-Pacific and Rest of the World are the most attractive and growing markets in psoriatic arthritis pharmacotherapy. In Asia-Pacific China, India, Japan, South Korea and Australia are observed to be the leading geographies in psoriatic arthritis.

The psoriatic arthritis pharmacotherapy market is predominantly led by the players such as Pfizer, Inc., Amgen, Inc., Merck & Co, Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, Abbott Laboratories and Novartis International AG. It was observed that Abbott Laboratories, Johnson and Johnson and Amgen, Inc. account for the major market share in psoriatic arthritis pharmacotherapy.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Middle East and Africa
  • Latin America
This report provides comprehensive analysis of
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Read More Reports on Pharmaceutical Market: 

About us

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Inquiry Before Buying: 



Contact Us

Mr. Nachiket Ghumare
Corporate Office:
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States.

Browse market research blog:
https://pharmaceuticalmarket.wordpress.com/

Wednesday, 29 October 2014

Global Smart Watches Market - Research Report, Analysis and Forecast 2014 – 2020


The global smart watches market is expected to show a remarkable growth rate by coming years. One of the major factors contributing the growth of the global smart watches market is the entrance of big vendors in the market. The market has also witnessing an increase in R&D spending. The global leading players such as Sony, Samsung, Pebble, and Maritime have increased their R&D investments for smart watches. For that, they are entering into partnerships with value-added resellers and suppliers and investing in R&D activities. These increasing R&D investments are helping players to introduce new products with better integration ability and accuracy. This will help with the reduction in smart watch prices and lead to an increase in their adoption among consumers.


Although the various driving factors, the global smart watches market is retraining due to the lack of proper technology standards. In addition, this is a new and emerging technology and thus technology standards are not clearly defined. The wearable computing device has failed because of the bulkiness, ugly look, battery issues and weak functionality. However, after the launch of number of new smart watches, consumer perceptions have changed. Nowadays, smart watches have become an important accessory to smartphones and an independent communication device. In future, smart watches will have a screen which potentially run software and allows to serve a robust extension to smartphone operating systems and apps.

The global smart watches market is segmented into two major categories, on the basis of application into general consumers, sports and healthcare and others. The market is also segmented on the basis of product characteristics into companion devices and standalone smart watches.

The market is driven by factors such as the rapidly growing consumer electronics goods industry and its distinctive features. The rapid technological advancements and changing consumer preferences will also act as drivers for the global smart watches market. Other factors fuelling the growth of the global smart watch market are the growing adoption of wireless technologies and softwares. Also the continuous adoption of mobile processor technologies is driving the demand for this market.

Some of the factors inhibiting the growth of the global smart watches market are the lack of standardization in this technology. The growing penetration of electronic devices will serve as an opportunity, fuelling the growth of the global smart watches market.

Some of the key players in this market are ConnecteDevice Ltd., Google Inc., Martian Watches, Metawatch Ltd., Qualcomm Inc., Samsung Electronics Co. Ltd., Sony Corp., Apple Inc., Pebble Technology among others. Earlier the global smart watches market was dominated by players with relatively low brand image in the electronic device industry. However, after the entrance of new big vendors in the consumer electronic device industry, the demand and curiosity for smart watches have increased among the end consumers.


About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

Contact:
Transparency Market Research
90 State Street, 
Suite 700, 
Albany

NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453

Browse Market Research Blogs:

Tuesday, 22 July 2014

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018

Pills
Methicillin-resistant staphylococcus aureus (MRSA) infections are caused due to Staphylococcus aureus bacterium which infects different parts of the body. These infections are difficult to treat due to high degree of resistance of these pathogens to the most commonly used antibiotics such as methicillin, amoxicillin, penicillin and oxacillin. The bacterium infects different parts of the body namely, skin, surgical wounds, blood streams, lungs, IV or other sites where the tubes such as catheters enter the body or the urinary tract and cause infection which can be life threatening.

MRSA infection is known to spread by casual contact or through contaminated objects called community associated MRSA (CA MRSA). It may also be acquired in hospitals or health care settings - healthcare associated MRSA (HA MRSA) which is the most common form of MRSA infection. Community associated methicillin resistant S. aureus (CA-MRSA) infections are different from healthcare associated methicillin resistant S. aureus (HA-MRSA) considering their epidemiology and the characteristics of the strains which causes the infection. Overuse of antibiotics and use of potent drugs for less serious infections may also cause development of MRSA. The symptoms of infection depend on the site of infection and it can be diagnosed by laboratory testing.

One of the major drivers contributing to the market growth for MRSA drugs is increase in the prevalence of MRSA infections. In addition, growth in the government and non-government awareness programs has also become a key factor in improving the market growth. However, overcoming the tendency of pathogen for developing resistance to multi-drugs and increase in competition between the generic market players could impose a challenge to the market growth.

MRSA can be usually treated by antibiotics such as bactrim and vancomycin though the pathogen has started developing resistance for these drugs too owing to its constant adapting power to newly developed antibiotics. Other options for the treatment of MRSA infection are generics such as clindamycin and minocycline, and prime brand-names such as Tygacil, Cubicin, Zyvox, and Synercid. Some of these antibiotics are only available intravenously. The most effective way of controlling the spread of MRSA is practicing basic hygiene such as use of disposable gloves, washing hands before making direct contact with patients as well as proper wound care.

Geographically, North America leads this market and is followed by Europe. However, increase in the development of healthcare infrastructure in emerging economies forecasts growth in demand for MRSA drugs in Asia-Pacific and other parts of the world. Some of the major players in this market include Takeda Pharmaceutical Company Limited, Merck & Co., Inc, AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Cubist Pharmaceuticals, Inc., ViroPharma, Inc., Forest Laboratories, Inc., and Theravance, Inc.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Rest of the World
This report provides comprehensive analysis of
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About us
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Contact Us
Sheela AK
Corporate Office:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States.
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Monday, 9 June 2014

Global Digital Breast Tomosynthesis Market - Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

Medical_Devices copy
Brest cancer is one of the most common cancers among women, with an estimate of about 500,000 mortalities in 2011 according to the World Health Organization (WHO). Although breast cancer is considered as a disease of developed countries, its prevalence is rising rapidly in the developing countries owing to urbanization and adoption of sedentary and stressful lifestyle. According to WHO, in 2012 an estimated of 70,000 females in India died due to breast cancer, while in China about 48,000 deaths were recorded and in the U.S. 44,000 deaths were recorded for breast cancer. The survival rate varies across the globe based on diagnosis time and rate along with the availability and affordability of services, with about 80% in North America and 60% in middle income countries. High prevalence globally has led doctors and scientists to take serious measures for early detection for the cancer so that proper care and treatment can be given to the patient.


Developing technology is adding various innovative devices which have helped in early diagnosis of cancers. Digital breast tomosynthesis also referred to as 3D mammography, is one of the technologies being developed for detection and characterization of breast lesions. The technique involves multiple projection images which allow visualization of thin breast sections which reveals cancers buried within normal tissue, allowing better diagnosis of breast cancer. FDA approval of digital breast tomosynthesis, Selenia Dimensions System by Hologic, Inc. in 2011 has boosted the market. Quick adoption, fewer recalls and simultaneous market penetration supported the market growth. In 2013, GE received CE mark for SenoClaire, and entered the European market.


The company also plans for regulatory approval in the U.S. Currently the digital breast tomosynthesis market has been more inclined towards North America and Europe where expensive devices can be afforded by medical institutes. An article published by The Boston Globe in 2012 mentions that by 2012 the device was sold to about 300 institutes in the U.S. According to the U.S. FDA, each year about 40 million mammography procedures are performed in the U.S. alone. These procedures may be replaced with digital breast tomosynthesis as it is a better alternative and delivers better results.

As the demand for better breast cancer diagnosis increases, the market will hold grounds in Japan, China, India and Brazil, which are considered to be the most profitable opportunities in the future. High cost of the device is the major restraining force for the market growth in Asia-Pacific and Rest of the World. Majority of the buying of expensive medical devices is supported by funding from investors and government. Hence these intermediaries will decide the fate of digital breast tomosynthesis in the developing economies. Rising incidences of breast cancer will also contribute to the market expansion in the future. Thus entry in this lucrative market is also easier, if the device has been successful in the U.S. market. Increasing trend for medical tourism in these regions will also pressurize medical institutes to upgrade to newer technology to deliver better medical services. Countries in Latin America such as Brazil, Mexico, Venezuela and Colombia are developing rapidly.

Regulatory scenario in these regions is also favorable, where most of the countries taking support of U.S. FDA and CE approvals. In Mexico, New Health Accord came into effect in the year 2010 which stated that medical devices approved in the U.S. or Canada will receive quicker approval in the country. Chile also demands no additional regulatory and accepts devices approved in the U.S. Key players in the market include Hologic, Inc., GE Healthcare, Siemens, and Dexela Ltd. (subsidiary of Perkin Elmer).

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Rest of the World
This report provides comprehensive analysis of 
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.


About us

Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.




Contact Us

Sheela AK
Corporate Office:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States.

Tel: +1-518-618-1030

Browse Market Research Blogs: